March 13, 2023 -- Pfizer will acquire Seagen, a firm specializing in the discovery and development of treatments for cancer, the firms announced on Monday.
Under the terms of a merger agreement, Pfizer will pay $229 per Seagen share, for a total of $43 billion. The transaction was unanimously approved by the boards of directors of both firms.
Pfizer expects to finance the transaction substantially through $31 billion of new, long-term debt, and the balance from a combination of short-term financing and existing cash. The companies expect to complete the transaction in late 2023 or early 2024.
The proposed combination will double Pfizer's early-stage oncology clinical pipeline, contributing Seagen's specialization in antibody-drug conjugate (ADC) technology to Pfizer's extensive cancer portfolio.
ADCs work across a broad range of cancers to preferentially kill cancer cells, thereby limiting off-target toxicity. Seagen's portfolio includes three ADCs -- Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin) -- as well as the drug Tukysa (tucatinib).
Seagen anticipates $2.2 billion of revenue in 2023, a year-over-year increase of approximately 12%. Taking into consideration the expected growth trajectories for these medicines along with drug candidates that could emerge from Seagen's pipeline, Pfizer believes that Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with the potential for significant growth beyond 2030.
Copyright © 2023 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
